DeepMed Research

Diosmin

Generic Name: Diosmin

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₃₂O_₁₅

CAS Number: 520-27-4

Unique Ingredient Identifier: 7QM776WJ5N

Background: Chronic venous insufficiency is a common condition the western population. Compression and pharmacotherapy are frequently used to manage chronic venous insufficiency, improving circulation and symptoms of venous disease.

Diosmin is a bioflavonoid isolated from various plants or synthesized from hesperidin. It is used for the improvement of capillary fragility or venous insufficiency, including chronic venous insufficiency (CVI) and hemorrhoids. Diosmin is widely available over-the-counter and demonstrates a favourable a favorable safety profile.

Indication: Diosmin is used over-the-counter alone or with ingredients such as hesperidin and diosmetin to support vein and capillary function.

Associated Conditions: Capillary fragility, Circulatory Function, Haemorrhoids, Venous Insufficiency, Healthy capillaries, Healthy veins

Clinical Trials

Efficacy of Diosmin and Hesperidin on Early Rehabilitation After Total Knee Arthroplasty

Conditions: Total Knee Arthroplasty
Venous Insufficiency of Leg

Interventions: Drug: Diosmin and Hesperidin Combination

First Posted Date: 2024-12-31

Last Posted Date: 2025-05-02

Lead Sponsor: Ankara Etlik City Hospital

Target Recruit Count: 200

Registration Number: NCT06753448

Locations: 🇹🇷
Ankara Etlik City Hospital, Ankara, Yenimahalle, Turkey

Venoactive Drug Treatment of Pelvic Venous Disorders

Phase 3

Recruiting

Conditions: Pelvic Venous Disorders

Interventions: Drug: Micronized purified flavonoid fraction
Drug: Diosmin 600
Drug: Hesperidin+Diosmin combination 1000

First Posted Date: 2024-09-05

Last Posted Date: 2024-12-27

Lead Sponsor: Pirogov Russian National Research Medical University

Target Recruit Count: 150

Registration Number: NCT06584799

Locations: 🇷🇺
Pirogov Russian National Research Medical University, Moskva, Russian Federation

Clinical Study to Evaluate the Possible Efficacy and Safety of Diosmin and Hesperidin Combined Therapy in Patients With Helicobacter Pylori Infection

Phase 1

Recruiting

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Placebo
Drug: Daflon

First Posted Date: 2024-08-09

Last Posted Date: 2024-08-12

Lead Sponsor: Sadat City University

Target Recruit Count: 46

Registration Number: NCT06546111

Locations: 🇪🇬
National Liver Institute, Shibīn Al Kawm, Egypt

Outcomes of Different Treatment Options in Chronic Venous Disease

Not yet recruiting

Conditions: Chronic Venous Disease

Interventions: Procedure: Radiofrequency ablation using Closure fast
Drug: Daflon
Procedure: Aethoxysclerol
Device: Compression stocking

First Posted Date: 2024-03-19

Last Posted Date: 2024-06-28

Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Target Recruit Count: 2000

Registration Number: NCT06318988

Evaluation of the Effects of Diosmin/Hespiridin Combination on the Clinical Outcomes in Patients With Polycystic Ovary Syndrome

Phase 4

Not yet recruiting

Conditions: Poly Cystic Ovary Syndrome

Interventions: Drug: Daflon
Drug: Combined oral contraceptive
Drug: Metformin

First Posted Date: 2023-10-16

Last Posted Date: 2023-10-16

Lead Sponsor: Ain Shams University

Target Recruit Count: 120

Registration Number: NCT06083935

the Efficacy and Safety of Diosmin on Non-diabetic Patients With Non-alcoholic Steatohepatitis.

Phase 3

Recruiting

Conditions: Non Alcoholic Steatohepatitis

Interventions: Drug: Diosmin
Drug: Placebo

First Posted Date: 2023-07-12

Last Posted Date: 2023-07-12

Lead Sponsor: Tanta University

Target Recruit Count: 48

Registration Number: NCT05942547

Locations: 🇪🇬
Tanta University, Tanta, Egypt

Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis

Phase 3

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Diosmin and Hesperidin Combination

First Posted Date: 2023-03-06

Last Posted Date: 2025-04-25

Lead Sponsor: Alexandria University

Target Recruit Count: 80

Registration Number: NCT05756179

Locations: 🇪🇬
Alexandria university hospital, Alexandria, Egypt

Diosmin as Adjuvant Therapy in Treatment of Non-bleeding Peptic Ulcer

Phase 3

Recruiting

Conditions: Non-bleeding Peptic Ulcer

Interventions: Drug: Diosmin

First Posted Date: 2023-01-04

Last Posted Date: 2023-01-04

Lead Sponsor: Tanta University

Target Recruit Count: 44

Registration Number: NCT05670457

Locations: 🇪🇬
Tanta University, Tanta, El Gharbia, Egypt

the Efficacy and Safety of Diosmin in Patients With Ulcerative Colitis

Phase 3

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: Diosmin

First Posted Date: 2022-11-23

Last Posted Date: 2023-04-12

Lead Sponsor: Tanta University

Target Recruit Count: 60

Registration Number: NCT05626166

Locations: 🇪🇬
Tanta university hospital, Tanta, Egypt

Impact of Treatment With VENARUS® on the Level of Monocyte Chemoattractant Protein 1 in Varicose Veins Blood

Not Applicable

Completed

Conditions: Varicose Veins

Interventions: Drug: Diosmin / Hesperidin

First Posted Date: 2021-06-22

Last Posted Date: 2022-03-31

Lead Sponsor: Pirogov Russian National Research Medical University

Target Recruit Count: 30

Registration Number: NCT04933591

Locations: 🇷🇺
Pirogov Russian National Research Medical University, Moscow, Russian Federation

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy